Dr. Michael M. Levine, M.D.,
Nephrology (Kidney) (Nephrology Physician)
8635 W 3rd St, Ste#485w
Los Angeles, CA 90048
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 577
Licensed in California since 1980, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: Baylor College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
CA license C39575 (first issued 1980; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cedars-Sinai Medical Center Los Angeles, CA
- Cedar-Sinai Marina Del Rey Hospital Marina Del Rey, CA
Medical groups
- Tower Nephrology Medical Group (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 577
- Services billed
- 14,120
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 852 | 291 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 593 | 181 |
| Telephone medical discussion with physician, 11-20 minutes | 311 | 168 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 291 | 36 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 250 | 30 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 227 | 32 |
| Hemodialysis procedure with physician evaluation | 119 | 38 |
| Injection of drug or substance under skin or into muscle | 104 | 21 |
| Administration of influenza virus vaccine | 102 | 101 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 99 | 98 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Los Angeles, CA | 352 |
| Valsartan Other prescribers in Los Angeles, CA | 319 |
| Rosuvastatin Calcium Other prescribers in Los Angeles, CA | 304 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Los Angeles, CA | 252 |
| Amlodipine Besylate Other prescribers in Los Angeles, CA | 237 |
| Levothyroxine Sodium Other prescribers in Los Angeles, CA | 187 |
| Torsemide Other prescribers in Los Angeles, CA | 137 |
| Losartan Potassium Other prescribers in Los Angeles, CA | 127 |
| Allopurinol Other prescribers in Los Angeles, CA | 112 |
| Mounjaro (tirzepatide) Other prescribers in Los Angeles, CA | 107 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 141 payments worth $3,033 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $361 |
|---|---|
| Amgen Inc. | $287 |
| AstraZeneca Pharmaceuticals LP | $266 |
| Ardelyx, Inc. | $260 |
| Lilly USA, LLC | $220 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $216 |
| Opko Pharmaceuticals, LLC | $182 |
| Otsuka America Pharmaceutical, Inc. | $138 |
| Food and Beverage | $3,031 |
|---|---|
| Education | $1.86 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Apr 9, 2025 | Education Filspari · Kidney Disease · in-kind | $1.86 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $219,472 in research payments for these studies, mostly to the institutions running them.
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APP…
AstraZeneca UK Limited - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.